Vision Healthcare NV’s Post

𝗗𝗶𝘃𝗲𝗿𝘀𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗮𝘀 𝗮 𝗛𝗲𝗱𝗴𝗲 𝗶𝗻 𝗩𝗼𝗹𝗮𝘁𝗶𝗹𝗲 𝗠𝗮𝗿𝗸𝗲𝘁𝘀 In the ongoing debate over where generics companies should focus, STADA’s revenue split offers food for thought. About 40 % of its business comes from consumer health products, 40 % from generics and 20 % from specialty pharma. This mix illustrates how branded consumer health can underpin value just as much as scale in generics. The next question for STADA’s owners is whether to push further into consumer health for brand‑led resilience or into specialty pharma for margin expansion. Investors are rewarding diversification; consumer brands act as a stabiliser in volatile generics markets. For leaders in the sector, diversification isn’t about abandoning the core business. It’s about adding steady, brand‑driven cash flows that buffer volatility while still leveraging scale in generics. Where does your current portfolio leave you exposed, and what adjacent areas could hedge that risk?

Today, we announced Essity's result for Q3, 2025. Our efforts to drive growth and reduce costs have yielded results and the third quarter developed favourably in continued challenging market conditions. We had a strong output from our innovation pipeline in the quarter, launching innovations tailored to the needs of our customers and consumers. One example is TENA ProSkin Stretch Day & Night, a new unique incontinence product that is easy to put on and take off, making it easier for both the patient and healthcare professionals. You find our full report here: https://lnkd.in/dJ-tCP7A In parallel, we’re today launching measures that will create better conditions for us to reach more people with our leading hygiene and health products, capture market shares, and maximize the potential of our product portfolio. Watch the video where I share more reflections on the quarter and our measures for growth.

🚀 Zinzino – From Scandinavian niche player to global health tech innovator The Swedish company Zinzino is rapidly evolving into a true global player in the wellness and health market within network marketing. With a strong focus on personalized nutrition, innovation, and international expansion, Zinzino is also positioning itself as an exciting growth stock on the financial markets – despite the usual bumps along the way. ✨ The journey: Founded in 2005 by Hilde and Ørjan Sæle, Zinzino started as a direct distributor of coffee products. The real breakthrough came with the shift towards evidence-based health solutions – especially the Omega-3 BalanceOil and advanced blood tests, enabling consumers to optimize their nutrition and vital values in a truly personal way. 🌍 Today: • Products in 40+ countries • More than 100,000 independent distributors • A scalable business model that merges direct-to-consumer dynamics with the power of a tech company 📈 Results speak for themselves: In 2024, Zinzino crossed €200 million in revenue – proving it has outgrown the niche stage and entered the league of international growth companies. 👉 Read the full article here: Zinzino – Scandinavia’s Network Marketing Star #netcoo #nexteconomy #networkmarketing #zinzino #sweden #wellness

📊 𝗖𝗮𝘁𝘀 𝗡𝘂𝘁𝗿𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁 𝟮𝟬𝟮𝟱-𝟮𝟬𝟯𝟭: 𝗕𝘆 𝗧𝘆𝗽𝗲 & 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 The global 𝐂𝐚𝐭𝐬 𝐍𝐮𝐭𝐫𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 is evolving rapidly, with key segments like 𝐄𝐲𝐞 𝐂𝐚𝐫𝐞, 𝐃𝐞𝐧𝐭𝐚𝐥 𝐂𝐚𝐫𝐞, 𝐒𝐤𝐢𝐧 𝐂𝐚𝐫𝐞, 𝐃𝐢𝐠𝐞𝐬𝐭𝐢𝐯𝐞 𝐇𝐞𝐚𝐥𝐭𝐡, 𝐚𝐧𝐝 𝐦𝐨𝐫𝐞 driving growth across 𝐂𝐡𝐚𝐢𝐧 𝐏𝐞𝐭 𝐂𝐚𝐫𝐞 𝐒𝐭𝐨𝐫𝐞𝐬, 𝐏𝐫𝐢𝐯𝐚𝐭𝐞 𝐏𝐞𝐭 𝐒𝐡𝐨𝐩𝐬, 𝐎𝐧𝐥𝐢𝐧𝐞 𝐒𝐭𝐨𝐫𝐞𝐬, 𝐚𝐧𝐝 𝐨𝐭𝐡𝐞𝐫 𝐜𝐡𝐚𝐧𝐧𝐞𝐥𝐬. This in-depth report provides insights into market size, trends, regional dynamics, and competitive landscape, helping stakeholders make informed decisions for 2025-2031. 🔍 𝗪𝗵𝘆 𝗜𝗻𝘃𝗲𝘀𝘁 𝗶𝗻 𝗧𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁? 🏆 Comprehensive Forecast: Market size, sales volume, and ASP projections from 2025-2031. 🌎 Regional Insights: Detailed analysis for North America, Europe, Asia-Pacific, South America, Middle East & Africa. 📈 Growth Opportunities: Segment-wise analysis by Type & Application to identify niche markets. 🧩 Competitive Landscape: Profiles of top players like Bayer, Zesty Paws (part of H&H Group), Nestlé Purina North America, Virbac, and more. 🚀 Market Drivers & Trends: Key insights into consumer demand, industry dynamics, and innovation. 🔧 Strategic Guidance: Assessment of raw materials, suppliers, and industry chain. 🛒 Channel Analysis: Sales breakdown across offline and online distribution channels. 💡 Data-Driven Decisions: Quantitative and qualitative market insights for strategic planning. 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 𝗰𝗮𝗻 𝘁𝗿𝗮𝗰𝗸 𝗵𝗶𝗴𝗵-𝗴𝗿𝗼𝘄𝘁𝗵 𝗺𝗮𝗿𝗸𝗲𝘁𝘀 𝗯𝗲𝘁𝘄𝗲𝗲𝗻 𝟮𝟬𝟮𝟱-𝟮𝟬𝟯𝟭: https://lnkd.in/d-S3nnzr #CatsNutraceuticals #PetCareMarket #EyeCare #DentalCare #SkinCare #DigestiveHealth #PetNutrition #MarketForecast #BusinessInsights #CompetitiveAnalysis

In recent years, we’ve witnessed the emergence of the Parapharma channel — a relatively new route-to-market that’s gaining significant traction in the beauty and wellness FMCG space. Unlike traditional pharmacies, Parapharmacies don’t sell medicines. Instead, they focus on personal care, beauty, wellness, and hygiene products — often at accessible price points, and with a layout that combines retail convenience with a sense of trust and expertise. 🔸 A New Retail Model Parapharmacies offer consumers a curated range of fast-moving wellness and beauty products in a clean, medical-like environment — but without the regulatory constraints of pharmaceutical retail. Their value-driven pricing and targeted assortment are attracting a new shopper segment looking for trusted products at lower prices. 🔸 Impact on Traditional Pharma The rapid growth of Parapharma is challenging the traditional pharmacy channel. Pharmacies are now facing increased competition on categories like skincare, vitamins, hygiene, and personal care — areas that used to be part of their core basket. This is pushing pharmacies to rethink their pricing, assortment, and promotional strategies to remain competitive. 🔸 Opportunities for FMCG Brands & Distributors For FMCG players, this evolution opens a distinct, scalable channel with different dynamics. It calls for tailored commercial models, differentiated trade marketing plans, and specialized execution strategies to unlock its full potential — while maintaining strong presence in pharma. As Parapharma continues to expand, the ability to clearly define the role of each channel and adapt accordingly will be a key competitive edge. 👉 How is your organization leveraging the rise of Parapharma in your distribution strategy? Would love to hear and learn.. Tamer Consumer #FMCG #Parapharma #PharmaChannel #BeautyAndWellness #TradeMarketing #DistributionStrategy #RetailEvolution #ConsumerTrends

🚀 The Secret Engine Behind Celebrity and Athlete Brands: European B2B Insight Ever wondered how top celebrities, athletes, and influencers successfully launch their own lines of supplements, sports nutrition, or cosmetics? It's not about owning a factory—it's about smart partnership. They have the vision, the audience, and the brand. We are the Contract Manufacturer that brings their vision to life. By choosing us, you eliminate production headaches and focus solely on what matters: Market penetration and brand growth. Our Partnership Advantage: Focus on Scaling, Not Manufacturing We manage the entire supply chain, allowing you to bypass major operational hurdles and seize market share faster. 1. Zero Production Stress: We handle the complexity—from sourcing premium raw materials and developing a unique formula to testing, packaging, and certification. Your only concern is sales and marketing. 2. Accelerated Time-to-Market: While building a manufacturing facility takes years, we can get your finalized, ready-to-sell product on the shelves in a matter of months. Speed is essential for winning in the European market. 3. Scalable Volumes: Whether you need a low Minimum Order Quantity (MOQ) to test a new European region or high volumes for rapid scaling, our flexible capacity supports your growth at every stage. 4. Quality & Compliance Guarantee: We ensure your product meets all rigorous EU regulations and quality standards, de-risking your market entry and building immediate consumer trust. Your Role: Define the Brand. Our Role: Deliver the Certified Product. ❓ B2B Question for Founders & Brand Owners: What is the single biggest operational challenge holding back your product launch in Europe right now? https://lnkd.in/dBf-VcAq #B2B #PrivateLabel #ContractManufacturing #Nutraceuticals #Cosmetics #EuropeanMarket #SupplyChain #BrandGrowth #PrivateLabelSupplements #EUExpansion #Liftingcream #cosmoceustics #GMPCertified #CustomFormulation #InnovationInBeauty #SportsNutrition #HealthcareProducts #CosmeticBrands #FoodSupplements #PrivateLabelBeauty #MarketEntry #BusinessGrowth #WhiteLabel #ScaleUp #ProductLaunch #MadeInEurope #BeautyTech #HealthAndWellness

This week at Initials CX, we brought together forward-thinking brands across FMCG, alcohol, and nutrition to explore “The New Future of Food.”   Hosted by Simon Callender, with expert insights from Professor Jason Halford, we unpacked how weight loss drugs are redefining our industry - from game-changing product innovation, to new messaging strategies, brand re-framing, and much more.   Curious to hear more? Comment below and we’ll send the report straight to your inbox.

𝐌𝐚𝐣𝐨𝐫 𝐃𝐚𝐢𝐫𝐲 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐔𝐩𝐝𝐚𝐭𝐞: 𝐒𝐲𝐧𝐥𝐚𝐢𝐭 𝐭𝐨 𝐒𝐞𝐥𝐥 𝐍𝐨𝐫𝐭𝐡 𝐈𝐬𝐥𝐚𝐧𝐝 𝐀𝐬𝐬𝐞𝐭𝐬 𝐭𝐨 𝐀𝐛𝐛𝐨𝐭𝐭 𝐟𝐨𝐫 $𝟏𝟕𝟖𝐌 New Zealand-based Synlait Milk Limited has reached an agreement to sell its North Island operations to Abbott Laboratories’ local unit for NZ$307 million (≈ US$178 million) — a strategic move set to reshape both companies’ positions in the global dairy and infant nutrition markets. 𝙒𝙝𝙖𝙩’𝙨 𝙄𝙣𝙘𝙡𝙪𝙙𝙚𝙙 𝙞𝙣 𝙩𝙝𝙚 𝘿𝙚𝙖𝙡? Synlait’s Pōkeno manufacturing plant Auckland blending, canning, and warehousing facilities 𝙒𝙝𝙮 𝙄𝙩 𝙈𝙖𝙩𝙩𝙚𝙧𝙨: ✔️Financial Reset for Synlait: Proceeds will significantly reduce debt and strengthen its balance sheet. ✔️Employee Transition: Abbott will onboard the majority of Synlait’s staff at completion — a win for workforce stability. ✔️Abbott’s Growth Play: Expands its footprint in infant nutrition, building on its partnership with Synlait since 2020. ✔️Strategic Timing: Completion expected April 1, 2026, pending approvals, with strong backing from Synlait’s largest shareholder, Bright Dairy Holding. 𝙇𝙚𝙖𝙙𝙚𝙧𝙨𝙝𝙞𝙥 𝙄𝙣𝙨𝙞𝙜𝙝𝙩𝙨: 🔹George Adams, Synlait Chair: “This sale will strengthen the company’s financial position and secure a positive future for our people.” Richard Wyeth, Synlait CEO: “A much-needed step-change — delivering a stronger, simpler, and more secure Synlait.” This transaction reflects a broader industry trend: dairy producers optimizing portfolios, while global healthcare and nutrition leaders like Abbott double down on science-backed infant nutrition solutions. 𝐇𝐚𝐯𝐞 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬? 𝐖𝐞’𝐫𝐞 𝐇𝐞𝐫𝐞 𝐭𝐨 𝐇𝐞𝐥𝐩! 𝐅𝐞𝐞𝐥 𝐟𝐫𝐞𝐞 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐨𝐮𝐭 𝐭𝐨 𝐮𝐬 𝐚𝐭: sales@towardsfnb.com 𝐎𝐫 𝐖𝐚𝐧𝐭 𝐝𝐞𝐞𝐩𝐞𝐫 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐢𝐧𝐭𝐨 𝐭𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐚𝐧𝐝 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬 𝐬𝐡𝐚𝐩𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐟𝐨𝐨𝐝 𝐚𝐧𝐝 𝐛𝐞𝐯𝐞𝐫𝐚𝐠𝐞? 𝐕𝐢𝐬𝐢𝐭 𝐮𝐬: https://lnkd.in/deJ5gzBT #Synlait #Abbott #DairyIndustry #InfantNutrition #FoodAndBeverages #MergersAndAcquisitions